1-(4-methoxyphenyl)-2-(3-bromophenyl)acetylene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-methoxyphenyl)-2-(3-bromophenyl)acetylene
• 英文别名: 1-methoxy-4-(m-bromoethynyl)benzene；1-bromo-3-((4-methoxyphenyl)ethynyl)benzene；2-(m-bromophenyl)-4-methoxyphenylacetylene；1-Bromo-3-[2-(4-methoxyphenyl)ethynyl]benzene
• 化学式: C₁₅H₁₁BrO
• 分子量: 287.156
• InChiKey: SQUSGZOPKJMORH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(4-methoxyphenyl)-2-(3-bromophenyl)acetylene 在 三氟甲磺酸 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 9.5h， 生成 4,4'-(1-(3-bromophenyl)-3-((trifluoromethyl)sulfonyl)cyclobut-2-ene-1,2-diyl)bis(methoxybenzene)
  参考文献：
  名称：

  HFIP 介导的脱硫傅克环丁烯基化反应

  摘要：

  在1,1,1,3,3,3-六氟异丙醇（HFIP）中，使用偕双（三氟甲基）环丁烯作为易于获得的原料，顺利进行了几种（杂）芳香族化合物的弗里德尔-克来福特型环丁烯基化反应。环丁烯基阳离子。

  DOI：

  10.1002/chem.202400843
• 作为产物：
  描述：

  1-bromo-3-(bromoethynyl)benzene 在 bis-triphenylphosphine-palladium(II) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 1-(4-methoxyphenyl)-2-(3-bromophenyl)acetylene
  参考文献：
  名称：

  芳基乙炔基溴化锌的直接制备及其在交叉偶联反应中的应用

  摘要：

  已经开发了用于制备芳基乙炔基溴化锌的新型合成方案。如此获得的有机锌试剂已成功地用于随后的交叉偶联反应中，并与多种芳基卤化物以良好至极好的收率提供了相应的炔基化化合物。

  DOI：

  10.1016/j.tetlet.2017.07.020

文献信息

• Macrocyclic hepatitis C serine protease inhibitors
  申请人：Miao Zhenwei

  公开号：US20050153877A1

  公开（公告）日：2005-07-14

  The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I、II或III的化合物，或其药用可接受的盐、酯或前药： 其中W是取代或未取代的杂环环系。这些化合物抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的对象进行给药。本发明还涉及通过给主体投药包含本发明化合物的药物组合物来治疗主体HCV感染的方法。
• Pd-Catalyzed decarboxylative alkynylation of alkynyl carboxylic acids with arylsulfonyl hydrazides<i>via</i>a desulfinative process
  作者：Sheng Chang、Ying Liu、Shu Zhu Yin、Lin Lin Dong、Jian Feng Wang

  DOI：10.1039/c8nj02964d

  日期：——

  In the presence of a Pd(II)/P-ligand catalytic system, decarboxylative alkynylation of alkynyl carboxylic acids and arylsulfonyl hydrazides by desulfinative coupling could provide aryl alkynes in satisfactory yields by either judiciously selecting palladium catalysts or modulating phosphine ligands under mild conditions. The reported coupling reactions are very practical as they do not require the

  在Pd（II）/ P-配体催化体系的存在下，通过明智地选择钯催化剂或在温和条件下调节膦配体，通过脱硫偶联将炔基羧酸和芳基磺酰肼进行脱羧烷基化可以提供令人满意的收率的芳基炔烃。报道的偶联反应非常实用，因为它们不需要保护惰性气体或氧气，并且可以耐受许多官能团。
• MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Miao Zhenwei

  公开号：US20090304629A1

  公开（公告）日：2009-12-10

  The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及I、II或III式化合物，或其药学上可接受的盐、酯或前药： 其中W是取代或未取代的杂环环系。这些化合物能够抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包括上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给予包括本发明的化合物的制药组合物来治疗受试者的HCV感染的方法。
• Emission from Regioisomeric Bis(phenylethynyl)benzenes during Pulse Radiolysis
  作者：Shingo Samori、Sachiko Tojo、Mamoru Fujitsuka、Torben Ryhding、Aaron G. Fix、Brittany M. Armstrong、Michael M. Haley、Tetsuro Majima

  DOI：10.1021/jo900494j

  日期：2009.5.15

  Emission from charge recombination between radical cations and anions of a series of regioisomeric 1,4-, 1,3-, and 1,2-bis(phenylethynyl)benzenes (bPEBs) substituted by various electron donor and/or acceptor groups was measured during pulse radiolysis in benzene (Bz). The formation of bPEB in the excited singlet state ((1)bPEB*) can be attributed to the charge recombination between bPEB(center dot+) and bPEB(center dot-), which are initially generated from the radiolytic reaction. This mechanism is reasonably explained by the relationship between the annihilation enthalpy change (-Delta H degrees) for the charge recombination of bPEB(center dot+) and bPEB(center dot-) and excitation energy of (1)bPEB*. Since the degree of the pi-conjugation in the S-1 state and HOMO-LUMO levels of bPEB change with the substitution pattern of phenylacetylene groups on the central benzene ring and the various kinds of donor and/or acceptor group, the fine-tuning of the emission color and intensity of bPEB can be easily carried out during pulse radiolysis in Bz. For donor-acceptor-substituted bPEB, it was found that the difference in the charge transfer conjugated pathways between donor and acceptor substituents (linear-, cross-, and "bent"-conjugated pathways) strongly influenced the HOMO-LUMO energy gap.
• Yan, Jincan; Wang, Zhiyuan; Wang, Lei, Journal of Chemical Research, 2004, # 1, p. 71 - 73
  作者：Yan, Jincan、Wang, Zhiyuan、Wang, Lei

  DOI：——

  日期：——